Marksans Pharma
Marksans Pharma is an Indian publicly listed generic pharmaceutical manufacturer producing tablets, capsules, oral liquids, and ointments across four facilities in India, the US, and UK, distributing 300+ products through wholly-owned subsidiaries to retail chains, wholesalers, and hospitals in 50+ countries with 95% of revenue from regulated markets.
- Company typePublic
- Founded2001
- HeadquartersMumbai, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Marksans Pharma does
Marksans Pharma Limited is a publicly listed Indian pharmaceutical company (NSE: MARKSANS, BSE: 524404) that develops, manufactures, and markets finished dosage generic pharmaceutical formulations for global regulated markets. Founded in 2001 as a wholly-owned subsidiary of Glenmark Pharmaceuticals and spun off as an independent entity in 2003, the company operates four manufacturing facilities — two in Goa, India (Verna and North Goa), one in Farmingdale, USA (Time-Cap Labs), and one in Southport, UK — producing tablets, hard and soft gelatin capsules, oral liquids, and ointments. Combined annual capacity is 8 billion units, on track to double to 16 billion units following the Tevapharm India acquisition. The portfolio comprises 300+ products and 1,500+ SKUs across OTC consumer self-care (pain, cough/cold, allergy, digestive, vitamins, skin) and prescription therapeutic segments (cardiovascular, CNS, oncology, anti-diabetics, antibiotics), backed by 50+ FDA-approved products, 350+ filed dossiers, and 300+ ANDA/MA approvals.
The company runs a vertically integrated, B2B contract-manufacturing and distribution model. Revenue is generated through negotiated supply agreements with major retail chains, pharmacy wholesalers, and hospital systems in the US, UK, Europe, Australia, Canada, MENA, and emerging markets — 95% of revenue comes from regulated jurisdictions. Distribution is executed through wholly-owned subsidiaries: Time-Cap Labs (US), Bell's Healthcare and Relonchem (UK), Nova Pharmaceuticals (Australasia), Access Healthcare (MENA), and QliniQ B.V. (Netherlands, acquired June 2026). R&D is conducted across four centers with 50+ scientists accredited by US-FDA, UK MHRA, and Australian TGA. With FY26 consolidated revenue of approximately ₹29,509 million (~$355M USD) and net profit of ₹4,200.64 million, the company is positioned as a mid-tier Indian generic exporter with an accelerating M&A-led geographic expansion strategy across the US, EU, Canada, and Australasia.
Marksans Pharma firmographics
Firmographics- Name
- Marksans Pharma
- Legal name
- Marksans Pharma Limited
- Website
- https://marksanspharma.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Marksans Pharma is an Indian publicly listed generic pharmaceutical manufacturer producing tablets, capsules, oral liquids, and ointments across four facilities in India, the US, and UK, distributing 300+ products through wholly-owned subsidiaries to retail chains, wholesalers, and hospitals in 50+ countries with 95% of revenue from regulated markets.
- Ownership category
- akta.pro rank
Marksans Pharma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industry
- Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)
Keywords
Where Marksans Pharma is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices5 records
Markets served
Marksans Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Generic Pharmaceutical Formulations: Research, manufacturing, and marketing of finished dosage pharmaceutical formulations. Revenue generated from sale of generic drugs across OTC and prescription categories. The company operates in regulated markets (US, Europe, Australia) contributing 95% of revenue.
- OTC Products: Over-the-counter consumer self-care products including pain management, cough and cold, digestive health, vitamins, supplements, and anti-allergic medications. Sold through retail chains and pharmacies.
- Prescription (Rx) Drugs: Prescription medications for cardiovascular diseases, central nervous system disorders, diabetes, oncology, and antibiotics. Distributed through wholesalers, retailers, and hospitals.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | B2B pharmaceutical sales model |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels3 records
Marksans Pharma product offering
Product offeringCore offering
Marksans Pharma is a publicly listed Indian pharmaceutical company that researches, manufactures, and markets finished dosage generic pharmaceutical formulations, including tablets, capsules, oral liquids, and ointments, across OTC and prescription segments. The company operates four manufacturing facilities in India, the UK, and the USA, producing over 300 products and 1,500+ SKUs distributed to retailers, wholesalers, and pharmacy chains in regulated markets globally.
Product overview
Marksans Pharma operates a diversified pharmaceutical formulation business with four manufacturing facilities located in India (Verna Goa and North Goa), United States (Farmingdale), and United Kingdom (Southport). The company offers a comprehensive portfolio of 300+ products and 1500+ SKUs across two main categories: OTC Consumer Self-Care Products (Pain Management, Cough & Cold, Allergy, Digestive Health, Vitamins/Minerals/Supplements, Skin Care) and Prescription Rx Therapeutic Segments (Cardiovascular, CNS, Oncology, Anti-Diabetics, Anti-Biotics). The portfolio is supported by subsidiary brands including Bells Healthcare (UK), Nova Pharmaceuticals (Australia), Relonchem (UK), Time-Cap Labs (USA), Access Healthcare (UAE/MENA), and QliniQ BV (Netherlands). Manufacturing capabilities include tablets, hard/soft gelatin capsules, oral liquids, and ointments with accreditations from US FDA, UK MHRA, Australian TGA, EU Health Authority, Health Canada, and Japanese Health Authority.
Differentiator
Problem solved
Functional benefit
Brands
- Bells Healthcare: Over-the-counter and prescription pharmaceuticals brand specializing in own-label products including analgesics, cough and cold, pain relief, gastrointestinal, ear care, and skin care
- Nova
- Relonchem
- Time-Cap Labs
- QliniQ
Products and services
- OTC Consumer Self-Care Products Over-the-counter consumer healthcare products including pain management (arthritis), upper respiratory (cough & cold, allergy), digestive health, vitamins/minerals/supplements, and skin care products distributed through retail and pharmacy chains.
- Prescription (Rx) Therapeutic Segments Prescription pharmaceutical products covering cardiovascular system, central nervous system, oncology, anti-diabetics, and anti-biotics therapeutic segments, distributed to wholesalers, retailers, and hospitals.
- Bells Healthcare (Bell, Sons & Co. Druggists) Ltd UK-based manufacturer of over-the-counter and prescription pharmaceuticals with over 100 MHRA-registered licenses, specializing in own-label products across analgesics, cough and cold, pain relief, gastrointestinal, ear care, and skin care. Largest manufacturer of private-label and branded cough liquids in the UK.
- Nova Pharmaceuticals Australasia Australian pharmaceutical company engaged in R&D and marketing of generic OTC products with focus on analgesics, antihistamines, anti-fungal, anti-allergy, dermatology, essential oils, and gastrointestinal segments. All products comply with TGA Australia regulations.
- Relonchem Limited UK-based company engaged in licensing, marketing, and distribution of prescription generic pharmaceutical products to wholesalers, retailers, and hospitals. Portfolio includes own-label products in anti-diabetic, anti-hypertensive, anti-depressant, anti-cancer, anti-ulcerative, allergy relief, anti-viral, and pain relief categories.
- Time-Cap Labs Inc. US-based manufacturer of solid-dose generic pharmaceutical products operating in OTC and prescription pharmaceutical markets. Products include Gastrointestinal, Laxatives, Pain Management, Analgesics, Cold and Cough, and Anti-Allergy categories sold through major pharmacy chains, distributors, and wholesalers.
- Access Healthcare for Medical Products L.L.C. Dubai-based pharmaceutical marketing and promotion company providing strategic partners with opportunities to grow business in the MENA region, with in-depth knowledge of local pharmaceutical market and business culture.
- QliniQ BV Netherlands-based company representing world leading manufacturers of medical devices and medicines. Operates niche products across women's health, dermatology, respiratory care, and specialty segments, manufactured within EU with Netherlands, Germany, and Spain as main manufacturing countries.
Quantifiable outcome
- FY26 net profit grew 9.8% to ₹4,200.64 million
- +3 more outcomes
Companies that use Marksans Pharma
Customer profileNamed customers6 records
Segments6 records
Ideal customer profiles3 records
Marksans Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Marksans Pharma partnerships and signals
Strategic signalScale indicators13 records
Recent moves9 records
Expansion highlights6 records
Marksans Pharma competitors and assessment
Company assessmentDirect peers
- Lupin Limited: Indian-headquartered generic pharmaceutical manufacturer with a comparable global footprint across the US, Europe, and emerging markets, similar dosage-form portfolio (oral solids, injectables, complex generics), and similar revenue scale. Both compete head-to-head in US generic ANDAs and UK/EU markets.
- Alkem Laboratories: Indian pharmaceutical company with comparable India-manufacturing-plus-US-distribution model, similar therapeutic-area breadth across OTC and prescription generics, and overlapping US ANDA filings. Comparable revenue scale and growth profile.
- Cipla Limited: Indian-headquartered generic and OTC pharmaceutical company with global presence including US, Europe, and emerging markets. Overlaps with Marksans in respiratory/cough-and-cold OTC, soft-gel capabilities, and US ANDA portfolio.
- Glenmark Pharmaceuticals: Marksans was originally incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals before spinning off in 2003. Both are Indian-headquartered generic pharmaceutical companies with similar therapeutic-area focus and US/UK distribution presence, making Glenmark a direct legacy peer.
- Aurobindo Pharma: Large Indian generic pharmaceutical company with comparable manufacturing scale, US/EU regulatory approvals, and finished dosage form focus. Both target similar US generic opportunities and operate multi-site manufacturing across India with global distribution networks.
- Torrent Pharmaceuticals: Indian mid-cap generic pharmaceutical company with US and emerging-markets presence, comparable finished dosage form focus, and similar revenue scale. Marksans recently acquired three Teva entities (Ireland, Canada, Nova Australia), making Torrent a relevant market overlap peer.
- Zydus Lifesciences (Cadila Healthcare): Indian-headquartered pharmaceutical company with similar generic dosage-form portfolio, US ANDA pipeline, and global distribution. Operates in many of the same therapeutic categories as Marksans, including cardiovascular, CNS, and anti-diabetic segments.
- Strides Pharma Science: Indian-headquartered generic pharmaceutical company with comparable manufacturing footprint in India, US, and other regulated markets, and similar finished dosage form (tablets, capsules, liquids, ointments) focus at a similar revenue scale.
Broad incumbents
- Sun Pharmaceutical Industries: India's largest pharmaceutical company and the dominant Indian generic player globally. Operates across the same dosage forms and therapeutic areas as Marksans but at substantially greater scale, with broader specialty and branded-generic exposure.
- Dr. Reddy's Laboratories: India-headquartered integrated pharmaceutical company with comparable US generics franchise, similar ANDA-driven business model, and global manufacturing footprint. Larger scale and broader specialty/biologics pipeline than Marksans.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Marksans Pharma social profiles
Digital presenceMarksans Pharma compliance and trust
Trust signalCompliance5 records
Marksans Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Marksans Pharma leadership team
Management profileNumber of profiles
Profiles13 records
Marksans Pharma subsidiaries and ownership
Company hierarchySubsidiaries7 records
Marksans Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Marksans Pharma M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Marksans Pharma
What does Marksans Pharma do?
Marksans Pharma is a publicly listed Indian pharmaceutical company that researches, manufactures, and markets finished dosage generic pharmaceutical formulations, including tablets, capsules, oral liquids, and ointments, across OTC and prescription segments. The company operates four manufacturing facilities in India, the UK, and the USA, producing over 300 products and 1,500+ SKUs distributed to retailers, wholesalers, and pharmacy chains in regulated markets globally.
Is Marksans Pharma a public or private company?
Marksans Pharma is a public company. It is classified as public and is currently operating.
When was Marksans Pharma founded?
Marksans Pharma was founded in 2001. It employs 1,001 to 5,000 people.
Where is Marksans Pharma based?
Marksans Pharma is headquartered in Mumbai, India, in the Asia region.
How does Marksans Pharma make money?
Three revenue lines are on record. Generic Pharmaceutical Formulations are the primary driver. The others are OTC Products and prescription (Rx) Drugs.
Who are Marksans Pharma's main competitors?
Direct peers on record are Lupin Limited, Alkem Laboratories, Cipla Limited, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals, Zydus Lifesciences (Cadila Healthcare) and Strides Pharma Science. Broad incumbents are Sun Pharmaceutical Industries and Dr. Reddy's Laboratories.
Does Marksans Pharma have an API?
No public API is recorded for Marksans Pharma.
What industry is Marksans Pharma in?
Marksans Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 325412 and its SIC code is 2834.